- Zacks•11 days ago
Pluristem Therapeutics (PSTI) has completed patient enrollment in a phase II study on PLX-PAD cells for the treatment of intermittent claudication.
- Zacks•12 days ago
TherapeuticsMD, Inc. (TXMD) announced the publication of two manuscripts detailing with the results of the company's pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.
- American City Business Journals•14 days ago
The New England Venture Capital Association announced the addition of five new board members Tuesday, with a focus on investors who have a background in the digital health and biotech industries. "With the additions boasting deep, specific focuses in biotech company creation, pharmaceuticals, and digital health, the appointments support a growing focus on the Life Sciences community, and come at a time when the organization continues to broaden its offerings in that sector," NEVCA said in a press release announcing the moves. New board members have connections to public companies like Johnson & Johnson (JNJ), Alnylam (ALNY) and Epizyme (EPZM), as well as top local venture capital firms like Atlas Venture, Bain Capital Ventures and Flybridge Capital.
EPZM : Summary for Epizyme, Inc. - Yahoo Finance
Epizyme, Inc. (EPZM)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||9.15 x 100|
|Day's Range||9.60 - 10.25|
|52 Week Range||7.02 - 13.46|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.39|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|